Lipo-oxytocin-1
 | |
| Chemical and physical data | |
|---|---|
| Formula | C75H126N12O14S2 |
| Molar mass | 1484.02 g·mol−1 |
Lipo-oxytocin-1 (LOT-1) is a synthetic peptide and derivative of oxytocin that acts as an agonist of the oxytocin receptor.[1] The lipidation strategy was applied to oxytocin to create a new peptide with improved pharmacokinetics.[1] LOT-1 consists of oxytocin conjugated with two palmitoyl groups.[1] After adjusting for molecular weight (LOT-1 is ~1.5x the weight of oxytocin), oxytocin and LOT-1 are equipotent.[1] In addition, LOT-1 appears to have a significantly longer duration of effect relative to that of oxytocin.[1] It has yet to be determined whether LOT-1 possesses improved blood-brain-barrier permeability relative to oxytocin.[1]
See also
- Carbetocin
- Demoxytocin
- Merotocin
- Palmitoylation
References
- 1 2 3 4 5 6 Mizuno A, Cherepanov SM, Kikuchi Y, Fakhrul AA, Akther S, Deguchi K, Yoshihara T, Ishihara K, Shuto S, Higashida H (2015). "Lipo-oxytocin-1, a Novel Oxytocin Analog Conjugated with Two Palmitoyl Groups, Has Long-Lasting Effects on Anxiety-Related Behavior and Social Avoidance in CD157 Knockout Mice". Brain Sci. 5 (1): 3–13. doi:10.3390/brainsci5010003. PMC 4390788. PMID 25612002.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.